The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has made a significant change to the guidelines for the Chikungunya vaccine, IXCHIQ. This decision, announced on February 11, 2026, is based on recommendations from the Commission on Human Medicines (CHM), an independent expert advisory committee. The vaccine is now restricted to a specific age group and individuals with certain health conditions. But here's where it gets controversial...
The MHRA has decided that the vaccine should only be used in adults aged 18 to 59 years old. This means that individuals aged 60 and over, as well as those with high blood pressure, heart disease, diabetes, or chronic kidney disease, are now excluded from receiving the vaccine. And this is the part most people miss...
The decision also extends to individuals who are immunodeficient or immunosuppressed, including those with IgA (immunoglobulin A) deficiency, and those who have a history of thymus disorder and/or thymectomy. The CHM concluded that the benefits of vaccination remain favorable for individuals at risk of chikungunya infection who are aged 18-59 years and do not have the above conditions. However, caution is advised when vaccinating individuals with two or more underlying chronic health conditions.
The MHRA's decision is based on global safety data, which has revealed 28 cases of serious adverse reactions, with three resulting in fatal outcomes. The Chikungunya virus is found in subtropical regions of the Americas, Africa, Southeast Asia, India, and the Pacific Region, and is spread to humans by infected mosquitoes. The virus typically causes a sudden fever and severe joint pain, with symptoms usually resolving within 7 to 10 days. However, the MHRA's new guidelines are a significant change from the previous approval of the vaccine in February 2025, and the temporary pause in June 2025 for individuals aged 65 and over.
The MHRA is responsible for regulating all medicines and medical devices in the UK, ensuring they are effective and acceptably safe. All their work is underpinned by robust and fact-based judgments to ensure that the benefits justify any risks. So, what do you think? Do you agree with the MHRA's decision to restrict the use of the Chikungunya vaccine? Or do you think there are other factors to consider? Share your thoughts in the comments below!
